Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
57
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$122.89
Seasonality move
:
9.54%
Day range:
$121.37 - $124.39
52-week range:
$99.06 - $134.17
Dividend yield:
0%
P/E ratio:
17.32x
P/S ratio:
2.04x
P/B ratio:
1.78x
Volume:
1.6M
Avg. volume:
692.4K
1-year change:
2.74%
Market cap:
$7.4B
Revenue:
$3.8B
EPS (TTM):
$7.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$1B | $5.50 | 4.77% | 311.88% | $181.05 |
|
ALKS
Alkermes PLC
|
$380.6M | $0.71 | 1.1% | 13.18% | $34.08 |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$0.21 | -- | -49.47% | -- |
|
MCKPF
Mallinckrodt PLC
|
-- | -- | -- | -- | -- |
|
MDT
Medtronic PLC
|
$8.3B | $1.25 | 2.97% | 37.4% | $96.00 |
|
PRGO
Perrigo Co PLC
|
$1.1B | $0.81 | 3.85% | 711.98% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$123.00 | $181.05 | $7.4B | 17.32x | $0.00 | 0% | 2.04x |
|
ALKS
Alkermes PLC
|
$29.71 | $34.08 | $4.8B | 15.24x | $0.00 | 0% | 3.35x |
|
ITRM
Iterum Therapeutics PLC
|
$1.77 | -- | $29.3M | -- | $0.00 | 0% | 33.79x |
|
MCKPF
Mallinckrodt PLC
|
$0.12 | -- | $2.4M | -- | $0.00 | 0% | 0.00x |
|
MDT
Medtronic PLC
|
$81.03 | $96.00 | $103.9B | 24.78x | $0.70 | 3.43% | 3.22x |
|
PRGO
Perrigo Co PLC
|
$25.75 | -- | $3.5B | -- | $0.28 | 4.29% | 0.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
59.44% | 0.892 | 90.76% | 3.24x |
|
ALKS
Alkermes PLC
|
18.27% | 1.823 | 6.38% | 2.82x |
|
ITRM
Iterum Therapeutics PLC
|
-- | 1.002 | -- | -- |
|
MCKPF
Mallinckrodt PLC
|
62.86% | 0.000 | 73639.04% | 1.43x |
|
MDT
Medtronic PLC
|
36.83% | 0.411 | 24.65% | 1.17x |
|
PRGO
Perrigo Co PLC
|
51.01% | -0.407 | 132.76% | 1.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$943.4M | $260.2M | 4.84% | 12.28% | 24.6% | $388M |
|
ALKS
Alkermes PLC
|
$315M | $104.8M | 21.26% | 26.09% | 30.74% | $73.3M |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$6.2M | -- | -- | -- | -$13.1M |
|
MCKPF
Mallinckrodt PLC
|
$221.1M | $51.7M | -81.47% | -287.81% | 7.91% | $118.1M |
|
MDT
Medtronic PLC
|
$5.5B | $1.6B | 5.61% | 8.54% | 21.04% | $554M |
|
PRGO
Perrigo Co PLC
|
$404.4M | $113.4M | -1.8% | -3.43% | 7.3% | $15.1M |
Jazz Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes PLC has a net margin of 20.39% compared to Jazz Pharmaceuticals PLC's net margin of 24.43%. Jazz Pharmaceuticals PLC's return on equity of 12.28% beat Alkermes PLC's return on equity of 26.09%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B ALKSAlkermes PLC83.31% $0.55 $1.6B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a consensus price target of $181.05, signalling upside risk potential of 47.2%. On the other hand Alkermes PLC has an analysts' consensus of $34.08 which suggests that it could grow by 14.7%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC8 3 0 ALKSAlkermes PLC7 4 1 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.568, which suggesting that the stock is 43.191% less volatile than S&P 500. In comparison Alkermes PLC has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.793%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Alkermes PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Alkermes PLC quarterly revenues of $378.1M. Jazz Pharmaceuticals PLC's net income of $215.1M is higher than Alkermes PLC's net income of $92.4M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 17.32x while Alkermes PLC's PE ratio is 15.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 2.04x versus 3.35x for Alkermes PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M ALKSAlkermes PLC3.35x 15.24x $378.1M $92.4M
-
Which has Higher Returns JAZZ or ITRM?
Iterum Therapeutics PLC has a net margin of 20.39% compared to Jazz Pharmaceuticals PLC's net margin of --. Jazz Pharmaceuticals PLC's return on equity of 12.28% beat Iterum Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B ITRMIterum Therapeutics PLC-- -$0.46 -- -
What do Analysts Say About JAZZ or ITRM?
Jazz Pharmaceuticals PLC has a consensus price target of $181.05, signalling upside risk potential of 47.2%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 323.73%. Given that Iterum Therapeutics PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Iterum Therapeutics PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC8 3 0 ITRMIterum Therapeutics PLC0 0 0 -
Is JAZZ or ITRM More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.568, which suggesting that the stock is 43.191% less volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.404, suggesting its more volatile than the S&P 500 by 140.42%.
-
Which is a Better Dividend Stock JAZZ or ITRM?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ITRM?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Iterum Therapeutics PLC quarterly revenues of --. Jazz Pharmaceuticals PLC's net income of $215.1M is higher than Iterum Therapeutics PLC's net income of -$7.1M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 17.32x while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 2.04x versus 33.79x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M
-
Which has Higher Returns JAZZ or MCKPF?
Mallinckrodt PLC has a net margin of 20.39% compared to Jazz Pharmaceuticals PLC's net margin of -5.18%. Jazz Pharmaceuticals PLC's return on equity of 12.28% beat Mallinckrodt PLC's return on equity of -287.81%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B MCKPFMallinckrodt PLC43.74% -$1.33 $2.8B -
What do Analysts Say About JAZZ or MCKPF?
Jazz Pharmaceuticals PLC has a consensus price target of $181.05, signalling upside risk potential of 47.2%. On the other hand Mallinckrodt PLC has an analysts' consensus of -- which suggests that it could fall by --. Given that Jazz Pharmaceuticals PLC has higher upside potential than Mallinckrodt PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Mallinckrodt PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC8 3 0 MCKPFMallinckrodt PLC0 0 0 -
Is JAZZ or MCKPF More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.568, which suggesting that the stock is 43.191% less volatile than S&P 500. In comparison Mallinckrodt PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JAZZ or MCKPF?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mallinckrodt PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Mallinckrodt PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or MCKPF?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are larger than Mallinckrodt PLC quarterly revenues of $505.5M. Jazz Pharmaceuticals PLC's net income of $215.1M is higher than Mallinckrodt PLC's net income of -$26.2M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 17.32x while Mallinckrodt PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 2.04x versus 0.00x for Mallinckrodt PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M MCKPFMallinckrodt PLC0.00x -- $505.5M -$26.2M
-
Which has Higher Returns JAZZ or MDT?
Medtronic PLC has a net margin of 20.39% compared to Jazz Pharmaceuticals PLC's net margin of 15.11%. Jazz Pharmaceuticals PLC's return on equity of 12.28% beat Medtronic PLC's return on equity of 8.54%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B MDTMedtronic PLC64.94% $0.99 $77B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals PLC has a consensus price target of $181.05, signalling upside risk potential of 47.2%. On the other hand Medtronic PLC has an analysts' consensus of $96.00 which suggests that it could grow by 18.48%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Medtronic PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC8 3 0 MDTMedtronic PLC11 14 1 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.568, which suggesting that the stock is 43.191% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.999%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.43% to investors and pays a quarterly dividend of $0.70 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are smaller than Medtronic PLC quarterly revenues of $8.4B. Jazz Pharmaceuticals PLC's net income of $215.1M is lower than Medtronic PLC's net income of $1.3B. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 17.32x while Medtronic PLC's PE ratio is 24.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 2.04x versus 3.22x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M MDTMedtronic PLC3.22x 24.78x $8.4B $1.3B
-
Which has Higher Returns JAZZ or PRGO?
Perrigo Co PLC has a net margin of 20.39% compared to Jazz Pharmaceuticals PLC's net margin of -1.93%. Jazz Pharmaceuticals PLC's return on equity of 12.28% beat Perrigo Co PLC's return on equity of -3.43%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B PRGOPerrigo Co PLC37.19% -$0.15 $9.3B -
What do Analysts Say About JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a consensus price target of $181.05, signalling upside risk potential of 47.2%. On the other hand Perrigo Co PLC has an analysts' consensus of -- which suggests that it could grow by 39.03%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC8 3 0 PRGOPerrigo Co PLC0 0 0 -
Is JAZZ or PRGO More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.568, which suggesting that the stock is 43.191% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.517, suggesting its less volatile than the S&P 500 by 48.32%.
-
Which is a Better Dividend Stock JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.29% to investors and pays a quarterly dividend of $0.28 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -1178.74% of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or PRGO?
Jazz Pharmaceuticals PLC quarterly revenues are $1.1B, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Jazz Pharmaceuticals PLC's net income of $215.1M is higher than Perrigo Co PLC's net income of -$21M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 17.32x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 2.04x versus 0.80x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M PRGOPerrigo Co PLC0.80x -- $1.1B -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
